RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect

Lakefront Biotherapeutics NV

23/09/2026 06:56

** RBC upgrades biotech company Lakefront Biotherapeutics LKFT.AS to "outperform" from "sector perform" on gamgertamig's autoimmune potential
** The broker says the early antibody data suggests a safer profile than CAR-T therapies, or chimeric antigen receptor T-cell treatments, which recently faced severe halts
** RBC expects near-term data to de-risk the program and draw investor interest, noting that "we see this as an opportune time to step in" given the asset's zero implied value
** The broker adds that Lakefront expects to end 2026 with €2 billion ($2.29 billion) in cash, creating a substantial downside floor and generating meaningful income on interest
** The brokerage raises its TP by 73% to $45, adding a speculative risk qualifier and citing potential annual royalties of up to $885 million from the drug's future sales
** Out of 9 analysts that cover Lakefront Biotherapeutics NV, three rate the stock "strong buy" or "buy," four rate "hold" and two​ rate the stock "strong sell" or "sell" - LSEG data
($1 = 0.8752 euros)

(Reporting by Lucie Barbier in Gdansk)
((lucie.barbier@thomsonreuters.com))